Safety And Tolerability Of Extended-Release Guaifenesin In Patients With Cough, Thickened Mucus And Chest Congestion Associated With Upper Respiratory Tract Infection

Figures & data

Figure 1 Disposition of patients.

Table 1 Baseline Demographics

Characteristic	Guaifenesin (N = 552) n (%)
Sex  Female  Male	203 (36.78) 349 (63.22)
Ethnicity  Asian (Indian)	552 (100)
Age (years)  Mean ± SD  Median  Min, max	42.3 ± 15.46 40.0 18.0, 82.0
Height (cm)  Mean ± SD  Median  Min, max	160.8 ± 8.25 159.0 145.0, 185.0
Weight (kg)  Mean ± SD  Median  Min, max	62.5 ± 11.08 62.0 35.0, 117.0

Abbreviation: SD, standard deviation.

Table 2 Number And Percentage Of Patients With Treatment-Emergent Adverse Events

	Guaifenesin (N = 552) n (%)
All adverse events	28 (5.07)
Gastrointestinal disorders  Abdominal pain  Abdominal pain upper  Diarrhea  Dry mouth  Nausea	11 (1.99) 1 (0.18) 4 (0.72) 3 (0.54) 1 (0.18) 2 (0.36)
General disorders and administration site conditions  Malaise  Pain	3 (0.54) 2 (0.36) 1 (0.18)
Nervous system disorders  Dizziness  Headache	8 (1.45) 4 (0.72) 4 (0.72)
Psychiatric disorders  Anxiety	3 (0.54) 3 (0.54)
Respiratory, thoracic and mediastinal disorders  Rhinorrhea	2 (0.36) 2 (0.36)
Skin and subcutaneous tissue disorders  Pruritus	2 (0.36) 2 (0.36)

Notes: Treatment-emergent adverse events were those occurring after the start of study medication until the end of the study, and include any untoward medical occurrence, without necessarily having a causal relationship with the treatment.

Figure 2 Responses to the end-of-study patient questionnaire (N=552).

Notes: *Percentage calculated based on who would recommend ER guaifenesin to their family and friends for the treatment of chest congestion/chesty cough.
Abbreviation: ER, extended release.

Data Availability

Data supporting each of the outcomes reported herein are found on ClinicalTrials.gov (NCT03725085). Any additional data that may be available can be obtained by contacting the corresponding author.